Quince Therapeutics (NASDAQ:IRLA) Given New $86.00 Price Target at Citizens Jmp

Quince Therapeutics (NASDAQ:IRLA – Get Free Report) had its price target boosted by equities research analysts at Citizens Jmp from $77.00 to $86.00 in a research report issued to clients and investors on Monday, Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp‘s price target points to a potential upside of 116.08% from the stock’s current price.

A number of other analysts have also commented on the company. Raymond James Financial raised Quince Therapeutics to a “moderate buy” rating in a research note on Friday, October 9th. Weiss Ratings started coverage on shares of Quince Therapeutics in a research note on Tuesday, October 13th. They issued a “sell (d-)” rating for the company. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $86.00.

Check Out Our Latest Report on IRLA

Quince Therapeutics Stock Performance

IRLA stock opened at $39.80 on Monday. The company has a market capitalization of $40.60 million, a P/E ratio of -0.37 and a beta of 1.78. Quince Therapeutics has a 1 year low of $15.10 and a 1 year high of $909.98.

Quince Therapeutics Company Profile

(Get Free Report)

Quince Therapeutics, Inc. is a clinical-stage biotechnology company developing therapies for rare diseases and other conditions with significant unmet medical needs. The company’s technology platform is designed to use patients’ own red blood cells to deliver therapeutic compounds, with the goal of providing sustained treatment while limiting systemic exposure. Quince’s lead program is the EryDex System, an investigational treatment that loads dexamethasone sodium phosphate into a patient’s red blood cells for controlled release.

Further Reading

Receive News & Ratings for Quince Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quince Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.